慢性DSS诱导的结肠炎加剧帕金森病的表型及其病理特征在胃内轮暴露后
Nishant Sharma1,2, Monika Sharma1, Disha Thakkar3
1Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad 382355, Gujarat, India.
ACS pharmacology & translational science
|February 20, 2025
概括
预先存在的肠道炎症为帕金森病 (PD) 病理学准备大脑. 在结肠病小鼠中,慢性罗农暴露恶化了神经炎症和多巴胺能神经元损失,模仿了PD的进展.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 帕金森病 (PD) 与肠道炎症和神经毒素有关,影响α-synuclein (α-syn) 病理和大脑神经退行.
- 肠-大脑轴在PD病变发生过程中起着至关重要的作用,炎症可能使个体倾向于神经毒性侮辱.
研究的目的:
- 为了研究德克斯硫酸 (DSS) 诱导的结肠炎对多巴胺基神经元对罗特的脆弱性的长期影响.
- 确定先前存在的炎症性肠道环境如何影响帕金森病样病理的发展.
主要方法:
- 患有慢性结肠炎 (由DSS周期引起) 的小鼠在8周内通过胃内暴露于低剂量的罗诺.
- 评估了帕金森症行为,胃肠道 (GI) 炎症,α-syn表达,多巴胺基神经元损失和肠道微生物群组成 (16S rRNA测序).
主要成果:
- 暴露于罗特的结肠病小鼠显示结肠炎症增加,α-syn表达和紧结蛋白减少.
- 观察到肠道功能受损,握力减弱,黑体和脑干区域的多巴胺能神经元退化.
- 微生物群分析显示,与PD发展相关的特定细菌属 (如Catenibacterium,Turicibactor) 的变化.
结论:
- 长时间的低剂量罗诺暴露与肠道炎症相结合,预先条件为α-syn病理.
- 这种模型表明,炎症性肠道环境加剧神经退行,支持PD病变的肠-大脑轴.
相关概念视频
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429


